Biotec renews clinical trial agreement with Memorial Sloan Kettering Cancer Center

(Tromsø 13 November 2018) Biotec Pharmacon's (OSE:BIOTEC) subsidiary Biotec
BetaGlucans has renewed the clinical trial agreement (CTA) with Memorial Sloan
Kettering Cancer Center (MSK) to cover the full study period for the ongoing
clinical trial called «Phase I/II Trial of a Bivalent Vaccine with the
Immunological Adjuvant OPT-821, in Combination with Oral ß-glucan for High-Risk
Neuroblastoma".
The clinical trial combines the use of a Memorial Sloan Kettering developed
therapeutic vaccine against high-risk neuroblastoma in children with the use of
Biotec BetaGlucans' immunomodulatory product Soluble Beta-Glucan (SBG®). The CTA
regulates the obligation of supply of study drug from Biotec to finalise the
study, the obligation for MSK to provide Biotec with study data as well as how
intellectual property rights arising from the study shall be handled between the
parties.

The study has per end of October 2018 accrued 200 patients and has now been
expanded to treat up to 260 patients having high-risk neuroblastoma. In the
expanded and now randomised study, patients will either continue to be given SBG
from week 6 after the 3rd vaccination, or from start of the vaccine treatment in
order to investigate if SBG could induce an earlier adjuvant effect to the GD2
cancer antigen. The additional 60 patients are expected to be recruited to the
study protocol by end of 2019.

"Neuroblastoma is a devastating disease and we are proud to be associated with
research into finding treatment options for it. We are equally excited to extend
our long-lasting relationship with Memorial Sloan Kettering Cancer Center, and
look forward to follow the progress of the study", says CEO Christian Jørgensen